Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
Simone N KooleLeigh BruijsCristina FabrisKarolina SikorskaMaurits EngbersenJules H Schagen van LeeuwenHenk W R SchreuderRalph H HermansJacobus van der VeldenHenriette J G ArtsMaaike van HamPeter Van DamPeter VuylstekeMax LahayeGabe SonkeWillemien van DrielPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
Centrally-assessed recurrence-free survival analysis confirms the benefit of adding HIPEC to interval cytoreductive surgery in patients with stage III ovarian cancer, with fewer peritoneal recurrences. These results rule out radiological bias caused by the open-label nature of the study.
Keyphrases
- phase iii
- open label
- free survival
- phase ii
- clinical trial
- phase ii study
- study protocol
- minimally invasive
- double blind
- placebo controlled
- coronary artery bypass
- artificial intelligence
- randomized controlled trial
- machine learning
- squamous cell carcinoma
- radiation therapy
- coronary artery disease
- percutaneous coronary intervention
- deep learning